Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on minimally invasive neurostimulation therapy for moderate to severe obstructive sleep apnea. These documents offer detailed insight into how Inspire reports its financial results, risks, and corporate developments.
Annual reports on Form 10-K and quarterly reports on Form 10-Q contain management’s discussion and analysis of financial condition and results of operations, along with risk factor disclosures. In these filings, Inspire describes its dependence on Inspire therapy for revenues, coverage and reimbursement considerations, competition from other therapies and technologies, reliance on third-party suppliers and contract manufacturers, international operations, information technology and cybersecurity risks, and other factors that may affect future performance.
Current reports on Form 8-K document specific material events. Recent 8-K filings have covered quarterly and annual financial results, preliminary and unaudited revenue ranges, expectations regarding the release of valuation allowances on U.S. deferred tax assets, authorization of share repurchase programs, and leadership changes such as the transition and appointment of the Chief Financial Officer. These filings often incorporate press releases and investor presentation materials by reference.
Investors can also review compensatory arrangements and executive employment agreements described in 8-K items, which outline base salary, bonus targets, equity awards, severance terms, and change-of-control provisions for senior executives. Such disclosures provide transparency into Inspire’s governance and incentive structures.
On Stock Titan, Inspire’s SEC filings are updated as they are made available on EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly identify themes such as revenue drivers tied to Inspire therapy, guidance ranges, risk factors, and notable corporate actions, without replacing the need to consult the full official filings.
Inspire Medical Systems interim CFO Richard Buchholz disposed of 579 shares of common stock at
Inspire Medical Systems, Inc. CEO and President Herbert Timothy P. Herbert reported a tax-withholding disposition of 1,635 shares of common stock at
After this transaction, he directly holds 32,686 common shares. An additional 63,658 shares are held indirectly through the Timothy P. Herbert 2018 Family Continuation Trust c/u the Timothy P. Herbert 2018 Grantor Retained Annuity Trust.
Inspire Medical Systems, Inc. Chief People Officer Melissa Mann reported a Form 4 showing a tax-related share disposition. The company withheld 615 shares of common stock at $59.76 per share to satisfy taxes due upon vesting of a restricted stock unit award. After this withholding, she directly holds 7,651 common shares.
Inspire Medical Systems, Inc. officer John Rondoni reported a tax-related share disposition. On February 13, 2026, the company withheld 587 shares of common stock at $59.76 per share to cover taxes due on the vesting of a restricted stock unit award. After this withholding, Rondoni directly owned 12,883 common shares. This was a tax-withholding transaction, not an open-market sale.
Inspire Medical Systems, Inc. officer Jason P. Kelly reported a tax-related share disposition. On February 13, 2026, 551 shares of common stock were withheld by the company at $59.76 per share to satisfy taxes upon vesting of a restricted stock unit award. After this withholding, Kelly directly holds 3,990 shares of Inspire Medical Systems common stock.
Inspire Medical Systems, Inc. officer Carlton Weatherby reported a Form 4 showing a tax-withholding disposition of company stock. On February 13, 2026, 570 shares of common stock were withheld at $59.76 per share to cover taxes due upon vesting of a restricted stock unit award. After this withholding, Weatherby directly owned 6,560 common shares, indicating the transaction was for tax purposes rather than an open-market sale.
Inspire Medical Systems, Inc. reported that officer Bryan K. Phillips had 579 shares of common stock withheld on a tax-withholding disposition related to the vesting of a restricted stock unit award. The shares were valued at $59.76 each, leaving him with 12,491 directly held shares afterward.
Inspire Medical Systems, Inc. received an updated ownership report from several Citadel-affiliated entities and Kenneth Griffin. The group may be deemed to beneficially own up to 527,217 Shares of Inspire Medical common stock, representing 1.8% of the Shares outstanding as of October 29, 2025.
Individual entities report smaller portions, such as Citadel Advisors–affiliated entities at 174,644 Shares (0.6%) and Citadel Securities LLC at 155,467 Shares (0.5%). The filers certify the securities are not held for the purpose of changing or influencing control of Inspire Medical.
Inspire Medical Systems describes its business built around Inspire, a fully implantable, closed-loop neurostimulation system for moderate to severe obstructive sleep apnea (OSA). The device gently stimulates the hypoglossal nerve during sleep to keep the airway open and is implanted in a 30‑ to 90‑minute outpatient procedure, with a battery designed to last about 11 years.
The company highlights extensive clinical evidence, including its pivotal STAR trial showing about a 70% median reduction in apnea‑hypopnea index from 29.3 to 9.0 events per hour at 12 months and sustained benefit to five years, and real‑world ADHERE registry data where patients used therapy 5.7 hours per night with 90% satisfaction and 92% willing to choose the procedure again. More than 125,000 patients have been treated across the U.S., Europe, and Asia.
Inspire sells primarily to hospitals and ambulatory surgery centers through a direct sales force, with 295 U.S. sales territories and 21 outside the U.S. It emphasizes broad insurance coverage, including positive policies from all large national commercial payors covering over 300 million U.S. lives, Medicare coverage through all seven MACs, and contracts with the Veterans Health Administration.
Inspire Medical Systems officer Carlton Weatherby, Chief Strategy and Growth Officer, reported a tax-withholding disposition of 327 shares of common stock on February 9, 2026 at $66.33 per share. After this transaction, Weatherby directly owned 7,130 shares of Inspire Medical Systems common stock.